

University of Colorado Cancer Center Minisymposium

Structural Biology in Cancer Drug Design

March 21, 2008

Research Hensel Phelps Auditorium - West, UCD, Aurora CO

Session 1 9:00-10:30

9:00-9:40 John Kuriyan (UC Berkeley) *Allosteric Control Mechanism in the Activation of the EGF Receptor*

9:50-10:20 Kate Ferguson (UPenn) *Mechanisms of inhibition of ligand-induced EGFR dimerization by therapeutic antibodies*

Coffee break 10:30-11:00

Session 2 11:00-12:30

11:00-11:40 David Cowburn (New York Structural Biology Center) *TBA*

11:50-12:20 Tomi Sawyer (Aileron Therapeutics) *Exploring Chemical Space in Protein-Protein Interaction Drug Discovery*

Lunch 12:30-2:00

Session 3 2:00-3:30

2:00-2:40 Stephen Burley (SGX Pharmaceutical) *Discovery and development of selective, orally bioavailable tyrosine kinase inhibitors for targeted treatment of human cancers*

2:50-3:20 Brian Blagg (U Kansas) *Designing Old Drugs for New Targets, a Case Study with Novobiocin*

Coffee break 3:30-4:00

Session 4 4:00-5:30

4:00-4:40 Maurizio Pellecchia (Burnham) *NMR- and fragment-based approaches to drug design*

4:50-5:20 Rick Artis (Plexxikon) *Scaffold-based Drug Discovery in Oncology*